Keywords
Last Name
Institution

Andrew S Kraft

Title
InstitutionMedical University of South Carolina
DepartmentHematology/Oncology
Address
vCardDownload vCard

    Collapse Overview 
    Collapse studies/trials
    Collapse keywords
    Cancer, Cancer/Sarcoma

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Padi SKR, Kraft AS. "Root"ing for successful T-ALL treatment. Blood. 2021 May 06; 137(18):2422-2423. PMID: 33956068.
      View in: PubMed
    2. Bearss JJ, Padi SK, Singh N, Cardo-Vila M, Song JH, Mouneimne G, Fernandes N, Li Y, Harter MR, Gard JM, Cress AE, Peti W, Nelson AD, Buchan JR, Kraft AS, Okumura K. EDC3 phosphorylation regulates growth and invasion through controlling P-body formation and dynamics. EMBO Rep. 2021 04 07; 22(4):e50835. PMID: 33586867.
      View in: PubMed
    3. Somaiah N, Van Tine BA, Wahlquist AE, Milhem MM, Hill EG, Garrett-Mayer E, Armeson KE, Schuetze SM, Meyer CF, Reuben DY, Elias AD, Read WL, Chawla SP, Kraft AS. A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma. Cancer. 2021 Mar 15; 127(6):894-904. PMID: 33231866.
      View in: PubMed
    4. Lim JT, Singh N, Leuvano LA, Calvert VS, Petricoin EF, Teachey DT, Lock RB, Padi M, Kraft AS, Padi SKR. PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis. Mol Cancer Ther. 2020 09; 19(9):1809-1821. PMID: 32753387.
      View in: PubMed
    5. Dishaw L, Yost E, Arzuaga X, Luke A, Kraft A, Walker T, Thayer K. A novel study evaluation strategy in the systematic review of animal toxicology studies for human health assessments of environmental chemicals. Environ Int. 2020 08; 141:105736. PMID: 32434117.
      View in: PubMed
    6. Singh N, Padi SKR, Bearss JJ, Pandey R, Okumura K, Beltran H, Song JH, Kraft AS, Olive V. PIM protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth. Mol Oncol. 2020 05; 14(5):974-990. PMID: 32146726.
      View in: PubMed
    7. Padi SKR, Singh N, Bearss JJ, Olive V, Song JH, Cardó-Vila M, Kraft AS, Okumura K. Phosphorylation of DEPDC5, a component of the GATOR1 complex, releases inhibition of mTORC1 and promotes tumor growth. Proc Natl Acad Sci U S A. 2019 10 08; 116(41):20505-20510. PMID: 31548394.
      View in: PubMed
    8. Song JH, Kang HJ, Luevano LA, Gokhale V, Wu K, Pandey R, Sherry Chow HH, Hurley LH, Kraft AS. Small-Molecule-Targeting Hairpin Loop of hTERT Promoter G-Quadruplex Induces Cancer Cell Death. Cell Chem Biol. 2019 08 15; 26(8):1110-1121.e4. PMID: 31155510.
      View in: PubMed
    9. Chatterjee S, Chakraborty P, Daenthanasanmak A, Iamsawat S, Andrejeva G, Luevano LA, Wolf M, Baliga U, Krieg C, Beeson CC, Mehrotra M, Hill EG, Rathmell JC, Yu XZ, Kraft AS, Mehrotra S. Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response. Clin Cancer Res. 2019 02 01; 25(3):1036-1049. PMID: 30327305.
      View in: PubMed
    10. Song JH, Singh N, Luevano LA, Padi SKR, Okumura K, Olive V, Black SM, Warfel NA, Goodrich DW, Kraft AS. Mechanisms Behind Resistance to PI3K Inhibitor Treatment Induced by the PIM Kinase. . 2018 12; 17(12):2710-2721. PMID: 30190422.
      View in: PubMed
    11. Daenthanasanmak A, Wu Y, Iamsawat S, Nguyen HD, Bastian D, Zhang M, Sofi MH, Chatterjee S, Hill EG, Mehrotra S, Kraft AS, Yu XZ. PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity. J Clin Invest. 2018 07 02; 128(7):2787-2801. PMID: 29781812.
      View in: PubMed
    12. Casillas AL, Toth RK, Sainz AG, Singh N, Desai AA, Kraft AS, Warfel NA. Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents. Clin Cancer Res. 2018 01 01; 24(1):169-180. PMID: 29084916.
      View in: PubMed
    13. Davis JA, Kraft A. Corrigendum to "Quantitative meta-analytic approaches to the systematic synthesis of data and hazard identification: A case-study of decreased pain sensitivity due to trimethylbenzene exposure" [Environ. Res. 158C (2017) 598-609]. Environ Res. 2017 11; 159:651. PMID: 28807322.
      View in: PubMed
    14. Sindhu S, Gimber LH, Cranmer L, McBride A, Kraft AS. Angiosarcoma treated successfully with anti-PD-1 therapy - a case report. J Immunother Cancer. 2017 07 18; 5(1):58. PMID: 28716069.
      View in: PubMed
    15. Davis JA, Kraft A. Quantitative meta-analytic approaches for the systematic synthesis of data and hazard identification: A case study of decreased pain sensitivity due to trimethylbenzene exposure. Environ Res. 2017 10; 158:598-609. PMID: 28719868.
      View in: PubMed
    16. Padi SKR, Luevano LA, An N, Pandey R, Singh N, Song JH, Aster JC, Yu XZ, Mehrotra S, Kraft AS. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset. Oncotarget. 2017 May 02; 8(18):30199-30216. PMID: 28415816.
      View in: PubMed
    17. An N, Cen B, Cai H, Song JH, Kraft A, Kang Y. Pim1 kinase regulates c-Kit gene translation. Exp Hematol Oncol. 2016; 5:31. PMID: 28042518.
      View in: PubMed
    18. Warfel NA, Sainz AG, Song JH, Kraft AS. PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species. . 2016 07; 15(7):1637-47. PMID: 27196781.
      View in: PubMed
    19. Song JH, Padi SK, Luevano LA, Minden MD, DeAngelo DJ, Hardiman G, Ball LE, Warfel NA, Kraft AS. Insulin receptor substrate 1 is a substrate of the Pim protein kinases. Oncotarget. 2016 Apr 12; 7(15):20152-65. PMID: 26956053.
      View in: PubMed
    20. An N, Xiong Y, LaRue AC, Kraft AS, Cen B. Activation of Pim Kinases Is Sufficient to Promote Resistance to MET Small-Molecule Inhibitors. Cancer Res. 2015 Dec 15; 75(24):5318-28. PMID: 26670562.
      View in: PubMed
    21. Yan P, Zhu A, Liao F, Xiao Q, Kraft A, Gonzales E, Perez R, Greenberg SM, Holtzman D, Lee JM. Minocycline reduces spontaneous hemorrhage in mouse models of cerebral amyloid angiopathy. Stroke. 2015 Jun; 46(6):1633-1640. PMID: 25944329.
      View in: PubMed
    22. Warfel NA, Kraft AS. PIM kinase (and Akt) biology and signaling in tumors. Pharmacol Ther. 2015 Jul; 151:41-9. PMID: 25749412.
      View in: PubMed
    23. Zemskova MY, Song JH, Cen B, Cerda-Infante J, Montecinos VP, Kraft AS. Regulation of prostate stromal fibroblasts by the PIM1 protein kinase. Cell Signal. 2015 Jan; 27(1):135-46. PMID: 25451079.
      View in: PubMed
    24. Saurabh K, Scherzer MT, Shah PP, Mims AS, Lockwood WW, Kraft AS, Beverly LJ. The PIM family of oncoproteins: small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets. Oncotarget. 2014 Sep 30; 5(18):8503-14. PMID: 25238262.
      View in: PubMed
    25. Song JH, An N, Chatterjee S, Kistner-Griffin E, Mahajan S, Mehrotra S, Kraft AS. Deletion of Pim kinases elevates the cellular levels of reactive oxygen species and sensitizes to K-Ras-induced cell killing. Oncogene. 2015 Jul; 34(28):3728-36. PMID: 25241892.
      View in: PubMed
    26. Chatterjee S, Thyagarajan K, Kesarwani P, Song JH, Soloshchenko M, Fu J, Bailey SR, Vasu C, Kraft AS, Paulos CM, Yu XZ, Mehrotra S. Reducing CD73 expression by IL1ß-Programmed Th17 cells improves immunotherapeutic control of tumors. Cancer Res. 2014 Nov 01; 74(21):6048-59. PMID: 25205101.
      View in: PubMed
    27. Din S, Konstandin MH, Johnson B, Emathinger J, Völkers M, Toko H, Collins B, Ormachea L, Samse K, Kubli DA, De La Torre A, Kraft AS, Gustafsson AB, Kelly DP, Sussman MA. Metabolic dysfunction consistent with premature aging results from deletion of Pim kinases. Circ Res. 2014 Jul 18; 115(3):376-87. PMID: 24916111.
      View in: PubMed
    28. Cen B, Xiong Y, Song JH, Mahajan S, DuPont R, McEachern K, DeAngelo DJ, Cortes JE, Minden MD, Ebens A, Mims A, LaRue AC, Kraft AS. The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling. Mol Cell Biol. 2014 Jul; 34(13):2517-32. PMID: 24777602.
      View in: PubMed
    29. Warren GW, Alberg AJ, Kraft AS, Cummings KM. The 2014 Surgeon General's report: "The health consequences of smoking--50 years of progress": a paradigm shift in cancer care. Cancer. 2014 Jul 01; 120(13):1914-6. PMID: 24687615.
      View in: PubMed
    30. Marshall DT, Ramey S, Golshayan AR, Keane TE, Kraft AS, Chaudhary U. Phase I trial of weekly docetaxel, total androgen blockade, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma. Clin Genitourin Cancer. 2014 Apr; 12(2):80-6. PMID: 24378335.
      View in: PubMed
    31. Twardowski PW, Beumer JH, Chen CS, Kraft AS, Chatta GS, Mitsuhashi M, Ye W, Christner SM, Lilly MB. A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy. Anticancer Drugs. 2013 Aug; 24(7):743-53. PMID: 23652277.
      View in: PubMed
    32. Roper SM, Zemskova M, Neely BA, Martin A, Gao P, Jones EE, Kraft AS, Drake RR. Targeted glycoprotein enrichment and identification in stromal cell secretomes using azido sugar metabolic labeling. Proteomics Clin Appl. 2013 Jun; 7(5-6):367-71. PMID: 23687070.
      View in: PubMed
    33. An N, Lin YW, Mahajan S, Kellner JN, Wang Y, Li Z, Kraft AS, Kang Y. Pim1 serine/threonine kinase regulates the number and functions of murine hematopoietic stem cells. Stem Cells. 2013 Jun; 31(6):1202-12. PMID: 23495171.
      View in: PubMed
    34. Cen B, Mahajan S, Wang W, Kraft AS. Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1. Cancer Res. 2013 Jun 01; 73(11):3402-11. PMID: 23585456.
      View in: PubMed
    35. Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, Agulnik M, Schuetze SM, Reed DR, Okuno SH, Ludwig JA, Keedy V, Rietschel P, Kraft AS, Adkins D, Van Tine BA, Brockstein B, Yim V, Bitas C, Abdullah A, Antonescu CR, Condy M, Dickson MA, Vasudeva SD, Ho AL, Doyle LA, Chen HX, Maki RG. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013 Apr; 14(4):371-82. PMID: 23477833.
      View in: PubMed
    36. An N, Kraft AS, Kang Y. Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice. J Hematol Oncol. 2013 Jan 29; 6:12. PMID: 23360755.
      View in: PubMed
    37. Cai H, Memarzadeh S, Stoyanova T, Beharry Z, Kraft AS, Witte ON. Collaboration of Kras and androgen receptor signaling stimulates EZH2 expression and tumor-propagating cells in prostate cancer. Cancer Res. 2012 Sep 15; 72(18):4672-81. PMID: 22805308.
      View in: PubMed
    38. Yoshimi M, Goyama S, Kawazu M, Nakagawa M, Ichikawa M, Imai Y, Kumano K, Asai T, Mulloy JC, Kraft AS, Takahashi T, Shirafuji N, Kurokawa M. Multiple phosphorylation sites are important for RUNX1 activity in early hematopoiesis and T-cell differentiation. Eur J Immunol. 2012 Apr; 42(4):1044-50. PMID: 22531928.
      View in: PubMed
    39. Song JH, Kraft AS. Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737. Cancer Res. 2012 Jan 01; 72(1):294-303. PMID: 22080570.
      View in: PubMed
    40. Kraft AS, Garrett-Mayer E, Wahlquist AE, Golshayan A, Chen CS, Butler W, Bearden J, Lilly M. Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade. . 2011 Jul 15; 12(2):119-24. PMID: 21532336.
      View in: PubMed
    41. Beharry Z, Mahajan S, Zemskova M, Lin YW, Tholanikunnel BG, Xia Z, Smith CD, Kraft AS. The Pim protein kinases regulate energy metabolism and cell growth. Proc Natl Acad Sci U S A. 2011 Jan 11; 108(2):528-33. PMID: 21187426.
      View in: PubMed
    42. Song JH, Kandasamy K, Zemskova M, Lin YW, Kraft AS. The BH3 mimetic ABT-737 induces cancer cell senescence. Cancer Res. 2011 Jan 15; 71(2):506-15. PMID: 21084274.
      View in: PubMed
    43. Cen B, Mahajan S, Zemskova M, Beharry Z, Lin YW, Cramer SD, Lilly MB, Kraft AS. Regulation of Skp2 levels by the Pim-1 protein kinase. J Biol Chem. 2010 Sep 17; 285(38):29128-37. PMID: 20663873.
      View in: PubMed
    44. Zemskova M, Lilly MB, Lin YW, Song JH, Kraft AS. p53-dependent induction of prostate cancer cell senescence by the PIM1 protein kinase. Mol Cancer Res. 2010 Aug; 8(8):1126-41. PMID: 20647331.
      View in: PubMed
    45. Lin YW, Beharry ZM, Hill EG, Song JH, Wang W, Xia Z, Zhang Z, Aplan PD, Aster JC, Smith CD, Kraft AS. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood. 2010 Jan 28; 115(4):824-33. PMID: 19965690.
      View in: PubMed
    46. Beharry Z, Zemskova M, Mahajan S, Zhang F, Ma J, Xia Z, Lilly M, Smith CD, Kraft AS. Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells. . 2009 Jun; 8(6):1473-83. PMID: 19509254.
      View in: PubMed
    47. Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, Livingston MB, Cooney MM, Hensley ML, Mita MM, Takimoto CH, Kraft AS, Elias AD, Brockstein B, Blachère NE, Edgar MA, Schwartz LH, Qin LX, Antonescu CR, Schwartz GK. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009 Jul 01; 27(19):3133-40. PMID: 19451436.
      View in: PubMed
    48. Zhang F, Beharry ZM, Harris TE, Lilly MB, Smith CD, Mahajan S, Kraft AS. PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells. . 2009 May; 8(9):846-53. PMID: 19276681.
      View in: PubMed
    49. Xia Z, Knaak C, Ma J, Beharry ZM, McInnes C, Wang W, Kraft AS, Smith CD. Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem. 2009 Jan 08; 52(1):74-86. PMID: 19072652.
      View in: PubMed
    50. Song JH, Kandasamy K, Kraft AS. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J Biol Chem. 2008 Sep 05; 283(36):25003-13. PMID: 18599488.
      View in: PubMed
    51. Mahajan S, Dammai V, Hsu T, Kraft AS. Hypoxia-inducible factor-2alpha regulates the expression of TRAIL receptor DR5 in renal cancer cells. Carcinogenesis. 2008 Sep; 29(9):1734-41. PMID: 18544564.
      View in: PubMed
    52. Kandasamy K, Kraft AS. Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region. . 2008 May; 7(5):1091-100. PMID: 18483298.
      View in: PubMed
    53. Beldner MA, Sherman CA, Green MR, Garrett-Mayer E, Chaudhary U, Meyer ML, Kraft AS, Montero AJ. Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer. BMC Cancer. 2007 Dec 20; 7:231. PMID: 18096059.
      View in: PubMed
    54. Hayslip J, Chaudhary U, Green M, Meyer M, Dunder S, Sherman C, Salzer S, Kraft A, Montero AJ. Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial. BMC Cancer. 2007 Dec 03; 7:221. PMID: 18053191.
      View in: PubMed
    55. Xiong X, Sui M, Fan W, Kraft AS. Cell cycle dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy. . 2007 Jul; 6(7):1067-73. PMID: 17568189.
      View in: PubMed
    56. Skorupa A, Beldner M, Kraft A, Montero AJ. Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma. . 2007 Jul; 6(7):1015-7. PMID: 17611408.
      View in: PubMed
    57. Ma J, Arnold HK, Lilly MB, Sears RC, Kraft AS. Negative regulation of Pim-1 protein kinase levels by the B56beta subunit of PP2A. Oncogene. 2007 Aug 02; 26(35):5145-53. PMID: 17297438.
      View in: PubMed
    58. Wang S, Zhang Y, Soosairajah J, Kraft AS. Regulation of RUNX1/AML1 during the G2/M transition. Leuk Res. 2007 Jun; 31(6):839-51. PMID: 17023045.
      View in: PubMed
    59. Sui M, Xiong X, Kraft AS, Fan W. Combination of gemcitabine antagonizes antitumor activity of paclitaxel through prevention of mitotic arrest and apoptosis. . 2006 Aug; 5(8):1015-21. PMID: 16855376.
      View in: PubMed
    60. Biggs JR, Peterson LF, Zhang Y, Kraft AS, Zhang DE. AML1/RUNX1 phosphorylation by cyclin-dependent kinases regulates the degradation of AML1/RUNX1 by the anaphase-promoting complex. Mol Cell Biol. 2006 Oct; 26(20):7420-9. PMID: 17015473.
      View in: PubMed
    61. Chen WW, Chan DC, Donald C, Lilly MB, Kraft AS. Pim family kinases enhance tumor growth of prostate cancer cells. Mol Cancer Res. 2005 Aug; 3(8):443-51. PMID: 16123140.
      View in: PubMed
    62. Biggs JR, Zhang Y, Peterson LF, Garcia M, Zhang DE, Kraft AS. Phosphorylation of AML1/RUNX1 regulates its degradation and nuclear matrix association. Mol Cancer Res. 2005 Jul; 3(7):391-401. PMID: 16046550.
      View in: PubMed
    63. Maki RG, Kraft AS, Scheu K, Yamada J, Wadler S, Antonescu CR, Wright JJ, Schwartz GK. A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer. 2005 Apr 01; 103(7):1431-8. PMID: 15739208.
      View in: PubMed
    64. Nikrad M, Johnson T, Puthalalath H, Coultas L, Adams J, Kraft AS. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. . 2005 Mar; 4(3):443-9. PMID: 15767553.
      View in: PubMed
    65. Wang Y, Quon KC, Knee DA, Nesterov A, Kraft AS. RAS, MYC, and sensitivity to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 2005 Feb 15; 65(4):1615-6; author reply 1616-7. PMID: 15735052.
      View in: PubMed
    66. Zhang Y, Biggs JR, Kraft AS. Phorbol ester treatment of K562 cells regulates the transcriptional activity of AML1c through phosphorylation. J Biol Chem. 2004 Dec 17; 279(51):53116-25. PMID: 15475366.
      View in: PubMed
    67. Nesterov A, Nikrad M, Johnson T, Kraft AS. Oncogenic Ras sensitizes normal human cells to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 2004 Jun 01; 64(11):3922-7. PMID: 15173003.
      View in: PubMed
    68. von Mehren M, Balcerzak SP, Kraft AS, Edmonson JH, Okuno SH, Davey M, McLaughlin S, Beard MT, Rogatko A. Phase II Trial of Dolastatin-10, a Novel Anti-Tubulin Agent, in Metastatic Soft Tissue Sarcomas. Sarcoma. 2004; 8(4):107-11. PMID: 18521404.
      View in: PubMed
    69. Roh M, Gary B, Song C, Said-Al-Naief N, Tousson A, Kraft A, Eltoum IE, Abdulkadir SA. Overexpression of the oncogenic kinase Pim-1 leads to genomic instability. Cancer Res. 2003 Dec 01; 63(23):8079-84. PMID: 14678956.
      View in: PubMed
    70. Yan B, Zemskova M, Holder S, Chin V, Kraft A, Koskinen PJ, Lilly M. The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem. 2003 Nov 14; 278(46):45358-67. PMID: 12954615.
      View in: PubMed
    71. Johnson TR, Stone K, Nikrad M, Yeh T, Zong WX, Thompson CB, Nesterov A, Kraft AS. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene. 2003 Aug 07; 22(32):4953-63. PMID: 12902978.
      View in: PubMed
    72. Ionov Y, Le X, Tunquist BJ, Sweetenham J, Sachs T, Ryder J, Johnson T, Lilly MB, Kraft AS. Pim-1 protein kinase is nuclear in Burkitt's lymphoma: nuclear localization is necessary for its biologic effects. Anticancer Res. 2003 Jan-Feb; 23(1A):167-78. PMID: 12680209.
      View in: PubMed
    73. Nesterov A, Ivashchenko Y, Kraft AS. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial cells. Oncogene. 2002 Feb 07; 21(7):1135-40. PMID: 11850832.
      View in: PubMed
    74. Matsuguchi T, Musikacharoen T, Johnson TR, Kraft AS, Yoshikai Y. A novel mitogen-activated protein kinase phosphatase is an important negative regulator of lipopolysaccharide-mediated c-Jun N-terminal kinase activation in mouse macrophage cell lines. Mol Cell Biol. 2001 Oct; 21(20):6999-7009. PMID: 11564882.
      View in: PubMed
    75. Biggs JR, Yang J, Gullberg U, Muchardt C, Yaniv M, Kraft AS. The human brm protein is cleaved during apoptosis: the role of cathepsin G. Proc Natl Acad Sci U S A. 2001 Mar 27; 98(7):3814-9. PMID: 11259672.
      View in: PubMed
    76. Lilly MB, Zemskova M, Frankel AE, Salo J, Kraft AS. Distinct domains of the human granulocyte-macrophage colony-stimulating factor receptor alpha subunit mediate activation of Jak/Stat signaling and differentiation. Blood. 2001 Mar 15; 97(6):1662-70. PMID: 11238105.
      View in: PubMed
    77. Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y, Kraft AS. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem. 2001 Apr 06; 276(14):10767-74. PMID: 11278284.
      View in: PubMed
    78. Vaishampayan U, Glode M, Du W, Kraft A, Hudes G, Wright J, Hussain M. Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma. Clin Cancer Res. 2000 Nov; 6(11):4205-8. PMID: 11106233.
      View in: PubMed
    79. Pawlowski JE, Nesterov A, Scheinman RI, Johnson TR, Kraft AS. NF-kappa B does not modulate sensitivity of renal carcinoma cells to TNF alpha-related apoptosis-inducing ligand (TRAIL). Anticancer Res. 2000 Nov-Dec; 20(6B):4243-55. PMID: 11205254.
      View in: PubMed
    80. Johnson TR, Biggs JR, Winbourn SE, Kraft AS. Regulation of dual-specificity phosphatases M3/6 and hVH5 by phorbol esters. Analysis of a delta-like domain. J Biol Chem. 2000 Oct 13; 275(41):31755-62. PMID: 10915787.
      View in: PubMed
    81. Zhang W, Geiman DE, Shields JM, Dang DT, Mahatan CS, Kaestner KH, Biggs JR, Kraft AS, Yang VW. The gut-enriched Kruppel-like factor (Kruppel-like factor 4) mediates the transactivating effect of p53 on the p21WAF1/Cip1 promoter. J Biol Chem. 2000 Jun 16; 275(24):18391-8. PMID: 10749849.
      View in: PubMed
    82. Pawlowski J, Kraft AS. Bax-induced apoptotic cell death. Proc Natl Acad Sci U S A. 2000 Jan 18; 97(2):529-31. PMID: 10639111.
      View in: PubMed
    83. Biggs JR, Kraft AS. The role of the Smad3 protein in phorbol ester-induced promoter expression. J Biol Chem. 1999 Dec 24; 274(52):36987-94. PMID: 10601254.
      View in: PubMed
    84. Gonzalez R, Ebbinghaus S, Henthorn TK, Miller D, Kraft AS. Treatment of patients with metastatic melanoma with bryostatin-1--a phase II study. Melanoma Res. 1999 Dec; 9(6):599-606. PMID: 10661772.
      View in: PubMed
    85. Weitman S, Langevin AM, Berkow RL, Thomas PJ, Hurwitz CA, Kraft AS, Dubowy RL, Smith DL, Bernstein M. A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study. Clin Cancer Res. 1999 Sep; 5(9):2344-8. PMID: 10499603.
      View in: PubMed
    86. Lilly M, Sandholm J, Cooper JJ, Koskinen PJ, Kraft A. The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway. Oncogene. 1999 Jul 08; 18(27):4022-31. PMID: 10435626.
      View in: PubMed
    87. Hedlund TE, Meech SJ, Srikanth S, Kraft AS, Miller GJ, Schaack JB, Duke RC. Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells. Cell Death Differ. 1999 Feb; 6(2):175-82. PMID: 10200564.
      View in: PubMed
    88. Kraft A, Weindel K, Ochs A, Marth C, Zmija J, Schumacher P, Unger C, Marmé D, Gastl G. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer. 1999 Jan 01; 85(1):178-87. PMID: 9921991.
      View in: PubMed
    89. Matsuguchi T, Kraft AS. Regulation of myeloid cell growth by distinct effectors of Ras. Oncogene. 1998 Nov 26; 17(21):2701-9. PMID: 9840934.
      View in: PubMed
    90. Burgess GS, Williamson EA, Cripe LD, Litz-Jackson S, Bhatt JA, Stanley K, Stewart MJ, Kraft AS, Nakshatri H, Boswell HS. Regulation of the c-jun gene in p210 BCR-ABL transformed cells corresponds with activity of JNK, the c-jun N-terminal kinase. Blood. 1998 Oct 01; 92(7):2450-60. PMID: 9746785.
      View in: PubMed
    91. Biggs JR, Ahn NG, Kraft AS. Activation of the mitogen-activated protein kinase pathway in U937 leukemic cells induces phosphorylation of the amino terminus of the TATA-binding protein. Cell Growth Differ. 1998 Aug; 9(8):667-76. PMID: 9716183.
      View in: PubMed
    92. Matsuguchi T, Lilly MB, Kraft AS. Cytoplasmic domains of the human granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor beta chain (hbetac) responsible for human GM-CSF-induced myeloid cell differentiation. J Biol Chem. 1998 Jul 31; 273(31):19411-8. PMID: 9677359.
      View in: PubMed
    93. Franklin CC, Srikanth S, Kraft AS. Conditional expression of mitogen-activated protein kinase phosphatase-1, MKP-1, is cytoprotective against UV-induced apoptosis. Proc Natl Acad Sci U S A. 1998 Mar 17; 95(6):3014-9. PMID: 9501207.
      View in: PubMed
    94. Turner T, Jackson WH, Pettit GR, Wells A, Kraft AS. Treatment of human prostate cancer cells with dolastatin 10, a peptide isolated from a marine shell-less mollusc. Prostate. 1998 Feb 15; 34(3):175-81. PMID: 9492845.
      View in: PubMed
    95. Srikanth S, Kraft AS. Inhibition of caspases by cytokine response modifier A blocks androgen ablation-mediated prostate cancer cell death in vivo. Cancer Res. 1998 Feb 15; 58(4):834-9. PMID: 9485043.
      View in: PubMed
    96. Lilly M, Kraft A. Enforced expression of the Mr 33,000 Pim-1 kinase enhances factor-independent survival and inhibits apoptosis in murine myeloid cells. Cancer Res. 1997 Dec 01; 57(23):5348-55. PMID: 9393759.
      View in: PubMed
    97. Asiedu C, Biggs J, Kraft AS. Complex regulation of CDK2 during phorbol ester-induced hematopoietic differentiation. Blood. 1997 Nov 01; 90(9):3430-7. PMID: 9345026.
      View in: PubMed
    98. Matsuguchi T, Zhao Y, Lilly MB, Kraft AS. The cytoplasmic domain of granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor alpha subunit is essential for both GM-CSF-mediated growth and differentiation. J Biol Chem. 1997 Jul 11; 272(28):17450-9. PMID: 9211889.
      View in: PubMed
    99. Franklin CC, Kraft AS. Conditional expression of the mitogen-activated protein kinase (MAPK) phosphatase MKP-1 preferentially inhibits p38 MAPK and stress-activated protein kinase in U937 cells. J Biol Chem. 1997 Jul 04; 272(27):16917-23. PMID: 9202001.
      View in: PubMed
    100. Sakai I, Kraft AS. The kinase domain of Jak2 mediates induction of bcl-2 and delays cell death in hematopoietic cells. J Biol Chem. 1997 May 09; 272(19):12350-8. PMID: 9139679.
      View in: PubMed
    101. Zhao Y, Loyer P, Li H, Valentine V, Kidd V, Kraft AS. Cloning and chromosomal location of a novel member of the myotonic dystrophy family of protein kinases. J Biol Chem. 1997 Apr 11; 272(15):10013-20. PMID: 9092543.
      View in: PubMed
    102. Yi W, Kim SO, Jiang J, Park SH, Kraft AS, Waxman DJ, Frank SJ. Growth hormone receptor cytoplasmic domain differentially promotes tyrosine phosphorylation of signal transducers and activators of transcription 5b and 3 by activated JAK2 kinase. Mol Endocrinol. 1996 Nov; 10(11):1425-43. PMID: 8923468.
      View in: PubMed
    103. Bignami GS, Wagner F, Grothaus PG, Rustagi P, Davis DE, Kraft AS. Biological activity of 26-succinylbryostatin 1. Biochim Biophys Acta. 1996 Jul 24; 1312(3):197-206. PMID: 8703988.
      View in: PubMed
    104. Zhang X, Zhang R, Zhao H, Cai H, Gush KA, Kerr RG, Pettit GR, Kraft AS. Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C. Cancer Res. 1996 Feb 15; 56(4):802-8. PMID: 8631017.
      View in: PubMed
    105. Biggs JR, Kudlow JE, Kraft AS. The role of the transcription factor Sp1 in regulating the expression of the WAF1/CIP1 gene in U937 leukemic cells. J Biol Chem. 1996 Jan 12; 271(2):901-6. PMID: 8557703.
      View in: PubMed
    106. Franklin CC, Kraft AS. Constitutively active MAP kinase kinase (MEK1) stimulates SAP kinase and c-Jun transcriptional activity in U937 human leukemic cells. Oncogene. 1995 Dec 07; 11(11):2365-74. PMID: 8570188.
      View in: PubMed
    107. Biggs JR, Kraft AS. Inhibitors of cyclin-dependent kinase and cancer. J Mol Med (Berl). 1995 Oct; 73(10):509-14. PMID: 8581512.
      View in: PubMed
    108. Asiedu C, Biggs J, Lilly M, Kraft AS. Inhibition of leukemic cell growth by the protein kinase C activator bryostatin 1 correlates with the dephosphorylation of cyclin-dependent kinase 2. Cancer Res. 1995 Sep 01; 55(17):3716-20. PMID: 7641182.
      View in: PubMed
    109. Sakai I, Nabell L, Kraft AS. Signal transduction by a CD16/CD7/Jak2 fusion protein. J Biol Chem. 1995 Aug 04; 270(31):18420-7. PMID: 7543102.
      View in: PubMed
    110. Adler V, Kraft AS. Regulation of AP-3 enhancer activity during hematopoietic differentiation. J Cell Physiol. 1995 Jul; 164(1):26-34. PMID: 7790394.
      View in: PubMed
    111. Frank SJ, Yi W, Zhao Y, Goldsmith JF, Gilliland G, Jiang J, Sakai I, Kraft AS. Regions of the JAK2 tyrosine kinase required for coupling to the growth hormone receptor. J Biol Chem. 1995 Jun 16; 270(24):14776-85. PMID: 7540178.
      View in: PubMed
    112. Zhao Y, Wagner F, Frank SJ, Kraft AS. The amino-terminal portion of the JAK2 protein kinase is necessary for binding and phosphorylation of the granulocyte-macrophage colony-stimulating factor receptor beta c chain. J Biol Chem. 1995 Jun 09; 270(23):13814-8. PMID: 7775438.
      View in: PubMed
    113. Dai T, Rubie E, Franklin CC, Kraft A, Gillespie DA, Avruch J, Kyriakis JM, Woodgett JR. Stress-activated protein kinases bind directly to the delta domain of c-Jun in resting cells: implications for repression of c-Jun function. Oncogene. 1995 Mar 02; 10(5):849-55. PMID: 7898927.
      View in: PubMed
    114. Franklin CC, McCulloch AV, Kraft AS. In vitro association between the Jun protein family and the general transcription factors, TBP and TFIIB. Biochem J. 1995 Feb 01; 305 ( Pt 3):967-74. PMID: 7848298.
      View in: PubMed
    115. Franklin CC, Adler V, Kraft AS. Phosphorylation of transcription factors. Methods Enzymol. 1995; 254:550-64. PMID: 8531714.
      View in: PubMed
    116. Dolan LR, Rutberg SE, Amin S, Emura M, Mohr U, Kraft A, Yokoyama K, Ronai Z. Regulation of c-jun by lung carcinogens in Clara cells of hamsters. Carcinogenesis. 1994 Dec; 15(12):2789-93. PMID: 8001236.
      View in: PubMed
    117. Frank SJ, Gilliland G, Kraft AS, Arnold CS. Interaction of the growth hormone receptor cytoplasmic domain with the JAK2 tyrosine kinase. Endocrinology. 1994 Nov; 135(5):2228-39. PMID: 7956946.
      View in: PubMed
    118. Polotskaya A, Zhao Y, Lilly MB, Kraft AS. Mapping the intracytoplasmic regions of the alpha granulocyte-macrophage colony-stimulating factor receptor necessary for cell growth regulation. J Biol Chem. 1994 May 20; 269(20):14607-13. PMID: 8182067.
      View in: PubMed
    119. Adler V, Unlap T, Kraft AS. A peptide encoding the c-Jun delta domain inhibits the activity of a c-jun amino-terminal protein kinase. J Biol Chem. 1994 Apr 15; 269(15):11186-91. PMID: 8157646.
      View in: PubMed
    120. Berkow RL, Schlabach L, Dodson R, Benjamin WH, Pettit GR, Rustagi P, Kraft AS. In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity. Cancer Res. 1993 Jun 15; 53(12):2810-5. PMID: 8504423.
      View in: PubMed
    121. Polotskaya A, Zhao Y, Lilly ML, Kraft AS. A critical role for the cytoplasmic domain of the granulocyte-macrophage colony-stimulating factor alpha receptor in mediating cell growth. Cell Growth Differ. 1993 Jun; 4(6):523-31. PMID: 8373736.
      View in: PubMed
    122. Franklin CC, Unlap T, Adler V, Kraft AS. Multiple signal transduction pathways mediate c-Jun protein phosphorylation. Cell Growth Differ. 1993 May; 4(5):377-85. PMID: 8390855.
      View in: PubMed
    123. Pulverer BJ, Hughes K, Franklin CC, Kraft AS, Leevers SJ, Woodgett JR. Co-purification of mitogen-activated protein kinases with phorbol ester-induced c-Jun kinase activity in U937 leukaemic cells. Oncogene. 1993 Feb; 8(2):407-15. PMID: 8426747.
      View in: PubMed
    124. Woodgett JR, Pulverer BJ, Nikolakaki E, Plyte S, Hughes K, Franklin CC, Kraft AS. Regulation of jun/AP-1 oncoproteins by protein phosphorylation. Adv Second Messenger Phosphoprotein Res. 1993; 28:261-9. PMID: 8398412.
      View in: PubMed
    125. Adler V, Polotskaya A, Wagner F, Kraft AS. Affinity-purified c-Jun amino-terminal protein kinase requires serine/threonine phosphorylation for activity. J Biol Chem. 1992 Aug 25; 267(24):17001-5. PMID: 1324919.
      View in: PubMed
    126. Franklin CC, Sanchez V, Wagner F, Woodgett JR, Kraft AS. Phorbol ester-induced amino-terminal phosphorylation of human JUN but not JUNB regulates transcriptional activation. Proc Natl Acad Sci U S A. 1992 Aug 01; 89(15):7247-51. PMID: 1496019.
      View in: PubMed
    127. Adunyah SE, Unlap TM, Franklin CC, Kraft AS. Induction of differentiation and c-jun expression in human leukemic cells by okadaic acid, an inhibitor of protein phosphatases. J Cell Physiol. 1992 May; 151(2):415-26. PMID: 1315324.
      View in: PubMed
    128. Kraft AS, Adler V, Hall P, Pettit GR, Benjamin WH, Briles DE. In vivo administration of bryostatin 1, a protein kinase C activator, decreases murine resistance to Salmonella typhimurium. Cancer Res. 1992 Apr 15; 52(8):2143-7. PMID: 1559218.
      View in: PubMed
    129. Kraft AS, Wang SS, Xiang J, Pouncey L, Kidd VJ. Regulation of the p58GTA cell division control-related protein kinase during phorbol 12-myristate 13-acetate-induced terminal differentiation of U937 cells. Oncogene. 1992 Mar; 7(3):501-6. PMID: 1549364.
      View in: PubMed
    130. Unlap T, Franklin CC, Wagner F, Kraft AS. Upstream regions of the c-jun promoter regulate phorbol ester-induced transcription in U937 leukemic cells. Nucleic Acids Res. 1992 Feb 25; 20(4):897-902. PMID: 1542579.
      View in: PubMed
    131. Lilly M, Brown C, Pettit G, Kraft A. Bryostatin 1: a potential anti-leukemic agent for chronic myelomonocytic leukemia. Leukemia. 1991 Apr; 5(4):283-7. PMID: 2027297.
      View in: PubMed
    132. Adunyah SE, Unlap TM, Wagner F, Kraft AS. Regulation of c-jun expression and AP-1 enhancer activity by granulocyte-macrophage colony-stimulating factor. J Biol Chem. 1991 Mar 25; 266(9):5670-5. PMID: 1900839.
      View in: PubMed
    133. William F, Wagner F, Karin M, Kraft AS. Multiple doses of diacylglycerol and calcium ionophore are necessary to activate AP-1 enhancer activity and induce markers of macrophage differentiation. J Biol Chem. 1990 Oct 25; 265(30):18166-71. PMID: 2120223.
      View in: PubMed
    134. Naftilan AJ, Gilliland GK, Eldridge CS, Kraft AS. Induction of the proto-oncogene c-jun by angiotensin II. Mol Cell Biol. 1990 Oct; 10(10):5536-40. PMID: 2119001.
      View in: PubMed
    135. Lilly M, Tompkins C, Brown C, Pettit G, Kraft A. Differentiation and growth modulation of chronic myelogenous leukemia cells by bryostatin. Cancer Res. 1990 Sep 01; 50(17):5520-5. PMID: 2386956.
      View in: PubMed
    136. Kraft AS, Wagner F, Housey GM. Overexpression of protein kinase C beta 1 is not sufficient to induce factor independence in the interleukin-3-dependent myeloid cell line FDC-P1. Oncogene. 1990 Aug; 5(8):1243-6. PMID: 2392326.
      View in: PubMed
    137. Kraft A, Arnold H, Zwingers T, Bodemann H, von Bültzingslöwen F, Hinkelbein W, Wannenmacher M. Role of thoracic radiotherapy combined with chemotherapy in limited stage small cell lung cancer (SCLC). A randomized multicenter phase III trial. Onkologie. 1990 Aug; 13(4):253-8. PMID: 2172884.
      View in: PubMed
    138. Fields AP, Pincus SM, Kraft AS, May WS. Interleukin-3 and bryostatin 1 mediate rapid nuclear envelope protein phosphorylation in growth factor-dependent FDC-P1 hematopoietic cells. A possible role for nuclear protein kinase C. J Biol Chem. 1989 Dec 25; 264(36):21896-901. PMID: 2600093.
      View in: PubMed
    139. William F, Haigler HT, Kraft AS. Lack of phosphorylation of lipocortin I in A431 epidermoid carcinoma cells treated with phorbol esters. Biochem Biophys Res Commun. 1989 Apr 28; 160(2):474-9. PMID: 2524194.
      View in: PubMed
    140. Kraft AS, William F, Pettit GR, Lilly MB. Varied differentiation responses of human leukemias to bryostatin 1. Cancer Res. 1989 Mar 01; 49(5):1287-93. PMID: 2917358.
      View in: PubMed
    141. Lilly MB, Kraft AS. Leukemia-differentiating activity expressed by the human melanoma cell line LD-1. Leuk Res. 1988; 12(3):217-25. PMID: 3163398.
      View in: PubMed
    142. May WS, Sharkis SJ, Esa AH, Gebbia V, Kraft AS, Pettit GR, Sensenbrenner LL. Antineoplastic bryostatins are multipotential stimulators of human hematopoietic progenitor cells. Proc Natl Acad Sci U S A. 1987 Dec; 84(23):8483-7. PMID: 3317410.
      View in: PubMed
    143. Kraft AS, Berkow RL. Tyrosine kinase and phosphotyrosine phosphatase activity in human promyelocytic leukemia cells and human polymorphonuclear leukocytes. Blood. 1987 Aug; 70(2):356-62. PMID: 3038210.
      View in: PubMed
    144. Kraft AS, Baker VV, May WS. Bryostatin induces changes in protein kinase C location and activity without altering c-myc gene expression in human promyelocytic leukemia cells (HL-60). Oncogene. 1987 May; 1(2):111-8. PMID: 3325877.
      View in: PubMed
    145. Gerbitz KD, Summer J, Schumacher I, Arnold H, Kraft A, Mross K. Enolase isoenzymes as tumour markers. J Clin Chem Clin Biochem. 1986 Dec; 24(12):1009-16. PMID: 3029273.
      View in: PubMed
    146. Kraft AS, Zuckerman KS. Production of multilineage hemopoietic growth-stimulating activities by a human melanoma cell line. Exp Hematol. 1986 Oct; 14(9):867-72. PMID: 3489637.
      View in: PubMed
    147. Bodemann H, Arnold H, Mann W, Hannich S, Kraft A, Löhr GW. [Neo-adjuvant chemotherapy of head and neck cancer]. Dtsch Med Wochenschr. 1986 Jul 11; 111(28-29):1097-100. PMID: 2426076.
      View in: PubMed
    148. Kraft AS. Effect of phorbol esters on the activity of purified transforming growth factors. Cancer Res. 1986 Apr; 46(4 Pt 1):1764-7. PMID: 3004705.
      View in: PubMed
    149. Kraft AS, Smith JB, Berkow RL. Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60. Proc Natl Acad Sci U S A. 1986 Mar; 83(5):1334-8. PMID: 3456591.
      View in: PubMed
    150. Bodemann HH, Arnold H, Wannenmacher M, Kraft A. [Staging and study procedure in small-cell bronchial carcinoma]. Dtsch Med Wochenschr. 1984 Jun 08; 109(23):910-2. PMID: 6086262.
      View in: PubMed
    151. Bodemann HH, Arnold H, Wannenmacher M, Kraft A. [Therapy of small-cell bronchial carcinoma]. Dtsch Med Wochenschr. 1984 Jun 08; 109(23):913-5. PMID: 6086263.
      View in: PubMed
    152. Kraft AS, Anderson WB, Cooper HL, Sando JJ. Decrease in cytosolic calcium/phospholipid-dependent protein kinase activity following phorbol ester treatment of EL4 thymoma cells. J Biol Chem. 1982 Nov 25; 257(22):13193-6. PMID: 7142138.
      View in: PubMed
    Kraft's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description